Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

Bayer (BAYRY) announced that it has acquired the exclusive marketing rights for cardiovascular candidate acoramidis in Europe from BridgeBio (BBIO) . The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V.Acoramidis is an investigational, next-generation, orally-administered, highly potent small molecule stabilizer of transthyretin (TTR).  It is being evaluated for the treatment of patients suffering from transthyretin amyloid cardiomyopathy (ATTR-CM).In ...